Renaissance Technologies
ADVM

Renaissance Technologies’s Adverum Biotechnologies ADVM Stock Holding History

Renaissance Technologies’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-363,496
Closed -$1.65M – 3197
2025
Q3 		$1.65M Sell
363,496
-207,173
-36% -$611K ﹤0.01% 2196
2025
Q2 		$1.23M Buy
570,669
+411,100
+258% +$1.15M ﹤0.01% 2401
2025
Q1 		$697K Buy
159,569
+29,964
+23% +$135K ﹤0.01% 2604
2024
Q4 		$605K Buy
129,605
+92,533
+250% +$623K ﹤0.01% 2759
2024
Q3 		$260K Sell
37,072
-99,185
-73% -$720K ﹤0.01% 3032
2024
Q2 		$935K Buy
136,257
+3,169
+2% +$29.5K ﹤0.01% 2361
2024
Q1 		$1.88M Sell
133,088
-54,677
-29% -$832K ﹤0.01% 2072
2023
Q4 		$1.41M Buy
187,765
+54,791
+41% +$500K ﹤0.01% 2176
2023
Q3 		$2M Buy
132,974
+11,310
+9% +$203K ﹤0.01% 1868
2023
Q2 		$1.93M Buy
121,664
+7,990
+7% +$84K ﹤0.01% 2015
2023
Q1 		$815K Buy
113,674
+6,250
+6% +$44.2K ﹤0.01% 2606
2022
Q4 		$623K Sell
107,424
-4,420
-4% -$33.5K ﹤0.01% 2818
2022
Q3 		$1.06M Buy
111,844
+2,540
+2% +$33.4K ﹤0.01% 2459
2022
Q2 		$1.31M Buy
109,304
+69,660
+176% +$730K ﹤0.01% 2524
2022
Q1 		$519K Sell
39,644
-24,374
-38% -$357K ﹤0.01% 3163
2021
Q4 		$1.13M Sell
64,018
-46,660
-42% -$934K ﹤0.01% 2555
2021
Q3 		$2.4M Buy
110,678
+29,750
+37% +$759K ﹤0.01% 1953
2021
Q2 		$2.83M Buy
80,928
+68,270
+539% +$3.68M ﹤0.01% 2012
2021
Q1 		$1.25M Buy
+12,658
New +$1.52M ﹤0.01% 2509
2020
Q4 		– Sell
-43,659
Closed -$4.5M – 3347
2020
Q3 		$4.5M Sell
43,659
-14,636
-25% -$2.19M ﹤0.01% 1632
2020
Q2 		$12.2M Sell
58,295
-50,120
-46% -$8.88M 0.01% 1113
2020
Q1 		$10.6M Sell
108,415
-37,170
-26% -$4.33M 0.01% 1125
2019
Q4 		$16.8M Sell
145,585
-123,715
-46% -$10.9M 0.01% 1103
2019
Q3 		$14.7M Sell
269,300
-116,450
-30% -$13.1M 0.01% 1146
2019
Q2 		$45.9M Buy
385,750
+6,320
+2% +$523K 0.04% 530
2019
Q1 		$19.9M Buy
379,430
+7,653
+2% +$309K 0.02% 973
2018
Q4 		$11.7M Buy
371,777
+17,527
+5% +$713K 0.01% 1208
2018
Q3 		$21.4M Buy
354,250
+15,490
+5% +$870K 0.02% 897
2018
Q2 		$18M Sell
338,760
-34,398
-9% -$2.07M 0.02% 985
2018
Q1 		$21.6M Buy
373,158
+117,690
+46% +$7.33M 0.02% 894
2017
Q4 		$8.94M Buy
255,468
+71,421
+39% +$2.35M 0.01% 1454
2017
Q3 		$6.72M Buy
184,047
+41,653
+29% +$1.16M 0.01% 1568
2017
Q2 		$3.56M Buy
142,394
+28,196
+25% +$771K ﹤0.01% 1926
2017
Q1 		$3.08M Buy
114,198
+17,228
+18% +$490K ﹤0.01% 2003
2016
Q4 		$2.81M Sell
96,970
-3,470
-3% -$113K ﹤0.01% 2039
2016
Q3 		$4.13M Buy
100,440
+26,926
+37% +$1.02M 0.01% 1726
2016
Q2 		$2.32M Buy
73,514
+45,644
+164% +$2.06M ﹤0.01% 2117
2016
Q1 		$1.44M Buy
27,870
+19,660
+239% +$1.1M ﹤0.01% 2405
2015
Q4 		$782K Buy
+8,210
New +$721K ﹤0.01% 2569

Renaissance Technologies's ADVM Position: Q4 2025 in Review

Renaissance Technologies sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 363,496 shares — an estimated $1.65M sold.

Renaissance Technologies first reported a position in ADVM in Q4 2015 and held it in 39 quarters. The position peaked at $45.9M in Q2 2019. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.

  • Renaissance Technologies reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
  • Renaissance Technologies sold 363,496 Adverum Biotechnologies shares in Q4 2025, an estimated $1.65M.
  • Renaissance Technologies first reported a position in Adverum Biotechnologies in Q4 2015 and held it in 39 quarters.
  • Renaissance Technologies's Adverum Biotechnologies position peaked at $45.9M in Q2 2019.
  • 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.